Edwards Lifesciences Corp (NYSE:EW) CEO Sells $4,910,465.00 in Stock
Edwards Lifesciences Corp (NYSE:EW) CEO Michael A. Mussallem sold 22,850 shares of the stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $214.90, for a total value of $4,910,465.00. Following the completion of the transaction, the chief executive officer now directly owns 95,770 shares in the company, valued at approximately $20,580,973. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of NYSE EW traded down $0.92 during trading hours on Wednesday, hitting $217.35. The company’s stock had a trading volume of 44,912 shares, compared to its average volume of 942,204. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.48 and a current ratio of 3.38. The stock has a market cap of $45.17 billion, a price-to-earnings ratio of 46.38, a P/E/G ratio of 2.74 and a beta of 0.84. Edwards Lifesciences Corp has a 12 month low of $136.44 and a 12 month high of $228.19. The business has a 50-day simple moving average of $216.86 and a 200-day simple moving average of $190.71.
Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, July 23rd. The medical research company reported $1.38 EPS for the quarter, beating analysts’ consensus estimates of $1.33 by $0.05. Edwards Lifesciences had a return on equity of 31.25% and a net margin of 18.29%. The business had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.04 billion. During the same quarter in the prior year, the company posted $1.24 EPS. Edwards Lifesciences’s quarterly revenue was up 15.2% compared to the same quarter last year. On average, equities research analysts forecast that Edwards Lifesciences Corp will post 5.34 EPS for the current year.
Several brokerages have issued reports on EW. BTIG Research reaffirmed a “hold” rating on shares of Edwards Lifesciences in a research note on Thursday, July 25th. Citigroup set a $159.00 price objective on Edwards Lifesciences and gave the company a “sell” rating in a report on Friday, July 26th. Zacks Investment Research upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $232.00 target price for the company in a research report on Thursday, July 25th. Jefferies Financial Group upped their price objective on shares of Edwards Lifesciences from $210.00 to $245.00 and gave the company a “buy” rating in a research note on Wednesday, July 24th. Finally, Raymond James increased their target price on shares of Edwards Lifesciences from $200.00 to $232.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. Two analysts have rated the stock with a sell rating, six have given a hold rating and fourteen have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $206.32.
About Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.
Featured Article: What are momentum indicators and what do they show?
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.